Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Nektar Therapeutics
Biotech
Nektar eczema asset 'checked all of the boxes' in phase 2
The results set rezpeg up to become “a preferred second-line therapy” in atopic dermatitis.
Darren Incorvaia
Feb 10, 2026 10:55am
Nektar claims ph. 2 alopecia success after excluding 4 patients
Dec 16, 2025 5:05pm
Nektar stock doubles as phase 2b eczema trial hits endpoints
Jun 24, 2025 9:20am
J&J vet jumps to Affinia—Chutes & Ladders
Feb 7, 2025 8:30am
Nektar CEO slams Lilly's 'egregious error,' laments lost time
Aug 8, 2023 8:18pm
Nektar accuses Lilly of botching eczema clinical trial analysis
Aug 7, 2023 8:30am
